Alaine Diagnostic LLC
Alaine Diagnostic LLC was paid $1.24M by Medicaid between Oct 2020 and Sep 2024, across 13 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 67% of everything it billed.
HOUSTON, TX 77074
Next to other Clinical Medical Laboratory providers in Texas
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 184 | $0.00 | |
| 2021 | 19,966 | $612K | |
| 2022 | 25,550 | $608K | |
| 2023 | 5,351 | $17K | |
| 2024incomplete | 1,375 | $2K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 67% | 16,759 | 7,629 | $835K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 20% | 16,141 | 7,456 | $253K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 10% | 17,459 | 7,950 | $129K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 1.5% | 468 | 279 | $19K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,421 | 238 | $3K |
| 82607 | <1% | 13 | 12 | $12.04 | |
| 80061 | Lipid panel | <1% | 16 | 14 | $10.69 |
| 80053 | Comprehensive metabolic panel | <1% | 20 | 18 | $8.43 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 25 | 20 | $6.20 |
| 81001 | <1% | 16 | 13 | $2.53 | |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | 0% | 44 | 38 | $0.00 |
| 84443 | Thyroid stimulating hormone (TSH) | 0% | 14 | 12 | $0.00 |
1 more codes
| 36415 | Collection of venous blood by venipuncture | 0% | 30 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
| Provider | Location | Paid |
|---|---|---|
| Bio Choice Laboratory, INC | Houston, TX | $35K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.